Joe Yeong
Dr. Joe Yeong’s main research focus is to understand and overcome the resistance of immunecheckpoint blockade immunotherapy. As an immuno-pathologist, his key vision is to bridge between immunologists and pathologists to better harness the advances of immunotherapy and further beyond. He is the pioneer in automation of quantitative multiplex immunohistochemistry, using clinical autostainers to study and quantitate tumour immune microenvironment in clinical samples, and has published > 100 papers in this field. His works on cancer immunology are included in multiple National Medical Research Council funded studies as well as pharmaceutical industry sponsored projects (>13 million dollars since 2017). He also served as a committee member in the World Immunotherapy Council, Society for Immunotherapy of Cancer (SITC) and is one of the organizers for its 2019 WIC Global Symposium as well as multiplex IF expert consensus meeting 2022. He also serves as Program Chair of one of the largest AI medical Imaging conferences, CLINICCAI-MICCAI. He is also a board member of Elsevier (Immunoinformatics), SLAS Technology (Journal), Frontiers and Pathogens. He serves as a Secretary (Executive) in Singapore Society of Oncology – Cancer Immunotherapy Consortium, Co-lead in Education/Diagnostic of Singhealth Duke-NUS Cell Therapy Centre as well as Advisor (Spatial Technology), Cancer Discovery Hub, National Cancer Centre.
Abstracts this author is presenting: